No products in the cart
Chonluten (T-34) (20mg)
Chonluten (T-34) peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What Is Chonluten (T-34) Peptide?
Chonluten is also known as tripeptide T-34. It is a cytogenetic complex consisting of short peptides which function primarily to normalize the mucous membrane cells of the lungs and the bronchial tube.
It is a gene regulator associated with inflammation and antioxidant activity and is involved in proliferation responses. It functions as an anti-inflammatory agent in the lungs, as it normalizes the mucosal functions of the lungs in conditions like asthma and chronic obstructive pulmonary disease (COPD).
Clinical studies have shown that Chonlunten is essential in treating and preventing lung disorders, chronic respiratory infections, and bronchitis and is effective in the maintaining the respiratory system of elderly patients.
Chonluten is tolerable and no side effects, complications, contraindications, or drug dependence is associated with its use.
Molecular Formula: C18H31N7O9
Molecular Weight: 318.27g/mol
Components: Peptide complex AC-7, microcrystalline cellulose, raw sugar, milk sugar (lactose), potato starch and twin-80
PubChem: CID 75007-24-8
Synonyms: T-34 tripeptide, EDG
Tripeptides in Bioregulation
Clinical studies have shown that several peptides (di, tri) play a role in slowing aging and increasing life span. These peptides are in running order to suppress oncogenes (genes that code for abnormal growth and spontaneous and induced tumors).
These tripeptides also play a role in regulating gene expression, including their role in cellular processes such as apoptosis.
According to Dr. Khavinson, chunloten and several other short peptides can bind to DNA and elicit their effects. It is one of few clinically essential peptides that introduce a new approach to health and diseases as we age.
Effects of Choluten in the Lungs
Clinical studies have shown changes in tissue activity of the lungs and alterations in DNA expression in ways that normalize the mucosal tissue of the bronchi due to the action of chonluten. According to Avolio et al., peptides like Choluten cooperate as natural inducers of TNF tolerance in monocyte, and act on macrophages as anti-inflammatory molecules during inflammatory and microbial-mediated activity. Chonluten is effective in treating and preventing bronchial function in acute and chronic respiratory diseases. It provides protection regardless of infectious or non-infectious etiology and helps maintain the respiratory system in both young and older adults.
Chonluten in the lung functions to regulate genes such as the c-Fos, health shock protein gene HSP70, SOD, COX-2, TNF-alpha, and genes in the antioxidant system.
The c-FOS protein is a potent regulator of cell proliferation, survival, and differentiation. This gene is most active in conditions like hypoxia and cellular destruction, and its effects are evident in the thickening of the mucosal wall of the bronchi.
The ability of chonluten to regulate the c-FOS activity can improve positive pathophysiological changes in asthma cases and COPD.
The use of chonluten in patients with chronic bronchitis associated with an asthmatic component contributed to reducing coughing and asthmatic attacks and decreasing the amount of sputum that shows a reduction in inflammatory and bronchospastic presentations of the disease.
Effects of Chonluten in the Gastrointestinal Tract (GIT)
It is important to note that research on the effects of chonlunten in the GIT is still ongoing. So far, the actions of chonluten in the GIT are almost similar to that in the lungs.
Clinical studies have shown that chonluten can decrease the inflammatory and vascular changes seen in the GIT sequel to inflammatory diseases like Crohn’s disease and Ulcerative colitis.
Chonluten and Covid-19
During the covid-19 pandemic, peptides with very active anti-inflammatory effects were of interest to scientists. The peptides may prevent the evolution of pathological conditions during covid-19 by putting a halt to SARS-Co V-2 viral proteins, which would, in turn, have Immuno and bronchoprotective effects on the cells of the lungs.
According to research, chonluten is essential in the treatment of bronchopulmonary pathology. It can also improve the effectiveness of standard therapy in chronic bronchitis with an asthmatic element and has a stress-protective effect.
In cases of low oxygen supply, chonlunten acts to improve physiological functions and physical performance. This effect has proven chonluten to be a practical ancillary in the fight against covid-19.
Chonluten is a short peptide that functions primarily to normalize the mucosal cells of the lungs and bronchial tube. Its function isn’t limited to the lungs and bronchial tubes. It carries out secondary roles in the GIT. It regulates genes involved in inflammatory and antioxidant activity and genes associated with proliferation responses to inflammation.
Chonluten carries out a regulatory function in the pulmonary mucosa. As a result, it may have applications in treating chronic inflammatory diseases of the lung such as asthma and COPD.
Chonluten exhibits minimal side effects as seen in pregnancy, breastfeeding, and in individuals who are intolerant to it. In mice, it exhibits low oral and excellent subcutaneous bioavailability.
- Khavinson, V. K., Lin’kova, N. S., & Tarnovskaya, S. I. (2016). Short Peptides Regulate Gene Expression. Bulletin of experimental biology and medicine, 162(2), 288–292. https://doi.org/10.1007/s10517-016-3596-7
- Avolio, F., Martinotti, S., Khavinson, V. K., Esposito, J. E., Giambuzzi, G., Marino, A., Mironova, E., Pulcini, R., Robuffo, I., Bologna, G., Simeone, P., Lanuti, P., Guarnieri, S., Trofimova, S., Procopio, A. D., & Toniato, E. (2022). Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International journal of molecular sciences, 23(7), 3607. https://doi.org/10.3390/ijms23073607
- Khavinson, V., Linkova, N., Kozhevnikova, E., Dyatlova, A., & Petukhov, M. (2022). Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International journal of molecular sciences, 23(14), 7733. https://doi.org/10.3390/ijms23147733
- Khavinson, V., Linkova, N., Dyatlova, A., Kuznik, B., & Umnov, R. (2020). Peptides: Prospects for Use in the Treatment of COVID-19. Molecules (Basel, Switzerland), 25(19), 4389. https://doi.org/10.3390/molecules25194389
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.